Details of Disease

General Information of Disease (ID: DISGYV3F)

• Disease Name: Lymphosarcoma
• Synonyms: malignant lymphoma (category); diffuse lymphoma; lymphosarcoma
• Definition: An antiquated term that refers to a non-Hodgkin lymphoma composed of small and medium sized lymphocytes.
• Disease Hierarchy:
  DISUX76L: Lymphatic system cancer
  DISS2Y8A: Non-hodgkin lymphoma
  DISGYV3F: Lymphosarcoma
• Disease Identifiers:
  MONDO ID: MONDO_0004638
  MESH ID: D008228
  UMLS CUI: C3714542
  MedGen ID: 811370
  SNOMED CT ID: 188498009

Drug-Interaction Atlas (DIA) of This Disease

This Disease is Treated as An Indication in 1 Approved Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Rituximab	DM1YVZT	Approved	Antibody	[1]

Molecular Interaction Atlas (MIA) of This Disease

This Disease Is Related to 8 DTT Molecule(s)

Gene Name	DTT ID	Evidence Level	Mode of Inheritance	REF
TFRC	TT8MG4S	Limited	Biomarker	[2]
TYMS	TTP1UKZ	moderate	Biomarker	[3]
CBS	TTVZJ7G	Strong	Biomarker	[4]
CHEK2	TT9ABMF	Strong	Biomarker	[5]
CSF2	TTNYZG2	Strong	Therapeutic	[6]
CYP2E1	TTWVHQ5	Strong	Biomarker	[7]
HLA-DRB1	TTUXSTW	Strong	Biomarker	[8]
BCL6	TTC9YX5	Definitive	Biomarker	[9]

This Disease Is Related to 2 DME Molecule(s)

Gene Name	DME ID	Evidence Level	Mode of Inheritance	REF
EPHX1	DELB4KP	Strong	Biomarker	[7]
FPGS	DECWT2V	Strong	Biomarker	[4]

This Disease Is Related to 9 DOT Molecule(s)

Gene Name	DOT ID	Evidence Level	Mode of Inheritance	REF
ALG1	OTVXPA9E	Strong	Posttranslational Modification	[10]
BHMT	OTYB6PXZ	Strong	Biomarker	[4]
CHIC2	OTNE3T6Z	Strong	Genetic Variation	[11]
MT1F	OTZVUYG1	Strong	Posttranslational Modification	[10]
MT1G	OTAV1OCR	Strong	Posttranslational Modification	[10]
MT1H	OT0MVBM6	Strong	Posttranslational Modification	[10]
MT1M	OTVT8PLU	Strong	Posttranslational Modification	[10]
MT1X	OT9AKFVS	Strong	Posttranslational Modification	[10]
SHMT1	OTIINA3J	Strong	Biomarker	[4]

References

• [1] Infusion reactions associated with the therapeutic use of monoclonal antibodies in the treatment of malignancy. Cancer Metastasis Rev. 1999;18(4):465-71.
• [2] The transferrin receptor part I: Biology and targeting with cytotoxic antibodies for the treatment of cancer.Clin Immunol. 2006 Nov;121(2):144-58. doi: 10.1016/j.clim.2006.06.010. Epub 2006 Aug 10.
• [3] Risk of non-Hodgkin lymphoma associated with polymorphisms in folate-metabolizing genes.Cancer Epidemiol Biomarkers Prev. 2005 Dec;14(12):2999-3003. doi: 10.1158/1055-9965.EPI-05-0515.
• [4] Gene-nutrient interactions among determinants of folate and one-carbon metabolism on the risk of non-Hodgkin lymphoma: NCI-SEER case-control study.Blood. 2007 Apr 1;109(7):3050-9. doi: 10.1182/blood-2006-07-034330.
• [5] Association of Germline CHEK2 Gene Variants with Risk and Prognosis of Non-Hodgkin Lymphoma.PLoS One. 2015 Oct 27;10(10):e0140819. doi: 10.1371/journal.pone.0140819. eCollection 2015.
• [6] DICE (dexamethasone, ifosfamide, cisplatin, etoposide) infusional chemotherapy for refractory or relapsed non-Hodgkin's lymphoma (NHL).Eur J Haematol Suppl. 2001 Jul;64:41-5.
• [7] Genetic polymorphisms of biotransformation enzymes in patients with Hodgkin's and non-Hodgkin's lymphomas.Hum Mol Genet. 2001 Jun 1;10(12):1265-73. doi: 10.1093/hmg/10.12.1265.
• [8] Variation in effects of non-Hodgkin lymphoma risk factors according to the human leukocyte antigen (HLA)-DRB1*01:01 allele and ancestral haplotype 8.1.PLoS One. 2011;6(11):e26949. doi: 10.1371/journal.pone.0026949. Epub 2011 Nov 9.
• [9] Suppression of human B cell activation by 2,3,7,8-tetrachlorodibenzo-p-dioxin involves altered regulation of B cell lymphoma-6.Toxicol Sci. 2015 Mar;144(1):39-50. doi: 10.1093/toxsci/kfu257. Epub 2014 Dec 26.
• [10] Physical and functional interaction of DNA methyltransferase 3A with Mbd3 and Brg1 in mouse lymphosarcoma cells.Cancer Res. 2005 Dec 1;65(23):10891-900. doi: 10.1158/0008-5472.CAN-05-1455.
• [11] Characterization of differentially expressed genes in the bovine T lymphoma cell line.Vet Immunol Immunopathol. 1998 Apr 16;62(3):209-19. doi: 10.1016/s0165-2427(98)00098-1.